In a landmark study performed by the Harvard Medical School, researchers have tested a prostate cancer drug called denosumab, which has been recently approved by the Food and Drug Administration that can possibly stop the spread of cancer cells to a patient's bones, according to ABCNews.com.
Prostate cancer has the ability to spread through the body through bone metastases as they develop from solid tumors. Doctors have theorized that inhibiting these cells can drastically reduce a person's risk of survival, and early signs are positive.
“This is the first agent of its kind to delay metastases, and not [though] chemotherapy or hormonal [treatment],” Dr. David Crawford, head of urologic oncology at the University of Colorado Health Sciences Center, told the news source. “This will be a very important modality to use in high risk patients.”
Regular screening is still one of the most effective means of preventing prostate cancer, but taking a vitamin supplement that supports prostate health can also be beneficial. Clinician's Choice Prostate Guardian is formulated with selenium, vitamin E and other nutrients to maintain proper prostate size and urine flow.